MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?
MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?
复制标题
DOI：
10.1038/sj.clpt.6100402
复制
发表时间：
2007-12-01
影响因子：
6.7
通讯作者：
Podda, A.
中科院分区：
文献类型：
--
作者：
O'Hagan, D. T.;Wack, A.;Podda, A.
MF59 佐剂已被纳入许可的流感疫苗中已有十年。因此，我们拥有大量临床数据来确定其效力和安全性。我们现在可以重新评估我们早期的临床前研究，并确定它们是否有助于预测人类反应。主要的教训是，小鼠模型可能很有价值，但必须提出正确的问题，并且必须正确使用模型。
The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.